Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway

Trial Profile

Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 13 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top